

Viking Therapeutics, Inc.
Form 4
May 06, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Lian Brian

(Last) (First) (Middle)

C/O VIKING THERAPEUTICS,
INC., 11119 NORTH TORREY
PINES ROAD, SUITE 50

(Street)

SAN DIEGO, CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol
Viking Therapeutics, Inc. [VKTX]

3. Date of Earliest Transaction
(Month/Day/Year)
05/04/2015

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify
below) President & CEO

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value \$0.00001 per share	05/04/2015		D	2,313,406 (1)	D (2) 1,336,594 (3)	D	
Common Stock, par value \$0.00001 per share	05/04/2015		A(4)	87,500	A \$ 0 1,424,094	D	
	05/04/2015		C	2,731	A (5) 1,426,825	D	

Edgar Filing: Viking Therapeutics, Inc. - Form 4

Common
Stock, par
value
\$0.00001
per share

Common
Stock, par
value
\$0.00001
per share

Common
Stock, par
value
\$0.00001
per share

05/04/2015

C

9,927

A

(5)

1,436,752

D

05/04/2015

F(6)

16,346

A

\$
9.49

1,453,098

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying (Instr. 3 and
						Date Exercisable	Expiration Date	Title
				Code	V	(A)	(D)	
Stock Option (Right to Buy)	\$ 9.49	05/04/2015		A	87,500	05/04/2015 ⁽⁷⁾	05/04/2025	Common Stock
Convertible Note due 2015	\$ 6 ⁽⁵⁾	05/04/2015		C		\$ 16,390	⁽⁵⁾	⁽⁵⁾ Common Stock
Convertible Note due 2015	\$ 6 ⁽⁵⁾	05/04/2015		C		\$ 59,563	⁽⁵⁾	⁽⁵⁾ Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lian Brian C/O VIKING THERAPEUTICS, INC. 11119 NORTH TORREY PINES ROAD, SUITE 50 SAN DIEGO, CA 92037	X		President & CEO	

Signatures

/s/ Michael Morneau, as
Attorney-in-Fact

05/06/2015

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Of the shares repurchased by the Issuer, 1,516,308 shares were fully vested and 797,098 were subject to vesting.
- (2) Shares were repurchased by the Issuer at a price of \$0.00001 per share.
Includes 460,534 shares of restricted stock that are subject to vesting, of which: (a) 18,869 shares will vest on May 26, 2015 and each month thereafter through and including August 26, 2015, (b) 18,868 shares will vest on September 26, 2015, (c) 183,095 will vest upon the achievement of a company milestone, and (d) 183,095 will vest upon the achievement of an additional company milestone.
- (4) Represents a restricted stock award of common stock under the Issuer's 2014 Equity Incentive Plan. One third of the shares subject to the restricted stock award shall vest on each one year anniversary of the grant date of the award.
The outstanding principal balance under the convertible note, plus all accrued and unpaid interest thereon, automatically converted into
- (5) shares of common stock upon the closing of the Issuer's initial public offering at a conversion price equal to 75% of the price at which shares were sold to the public. The convertible note had no expiration date.
Represents a restricted stock award of 28,193 shares of common stock granted under the Issuer's 2014 Equity Incentive Plan. All of the
- (6) shares subject to the restricted stock award vested immediately upon grant. In order to satisfy certain tax withholding obligations, the Issuer repurchased 11,847 of these shares from the Reporting Person.
- (7) 25% of the shares subject to the option were vested upon grant and 25% of the shares subject to the option will vest on each one year anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.